Allogene Therapeutics Price Chart
Allogene Therapeutics Volume Chart
Allogene Therapeutics Market Segments
Premarket
+0.00(+0.00%)
| Open | $2.62 |
|---|---|
| Close | $2.62 |
| Low | $2.62 |
| Low Change | 0.00 (0.00%) |
| High | $2.62 |
| High Change | +0.00 (+0.00%) |
| Range | $0.00 |
| Volume | 420 |
| Dollar Volume | $1.10K |
After Hours Yesterday
+0.00(+0.00%)
| Open | $2.63 |
|---|---|
| Close | $2.63 |
| Low | $2.63 |
| Low Change | 0.00 (0.00%) |
| High | $2.67 |
| High Change | +0.04 (+1.52%) |
| Range | $0.04 |
| Volume | 9.367K |
| Dollar Volume | $24.64K |
Regular Trading Hours Yesterday
-0.05(-1.87%)
| Open | $2.68 |
|---|---|
| Close | $2.63 |
| Low | $2.61 |
| Low Change | -0.07 (-2.61%) |
| High | $2.73 |
| High Change | +0.05 (+1.68%) |
| Range | $0.12 |
| Volume | 2.751M |
| Dollar Volume | $7.23M |
Premarket Yesterday
-0.03(-1.10%)
| Open | $2.73 |
|---|---|
| Close | $2.70 |
| Low | $2.70 |
| Low Change | -0.03 (-1.10%) |
| High | $2.74 |
| High Change | +0.01 (+0.37%) |
| Range | $0.04 |
| Volume | 8.899K |
| Dollar Volume | $24.03K |
Allogene Therapeutics Moving Averages
| 5 Day Moving Average (SMA5) | $2.49 |
|---|---|
| 10 Day Moving Average (SMA10) | $2.57 |
| 20 Day Moving Average (SMA20) | $2.32 |
| 50 Day Moving Average (SMA50) | $1.88 |
| 100 Day Moving Average (SMA100) | $1.60 |
| 200 Day Moving Average (SMA200) | $1.41 |
Allogene Therapeutics Statistics
| Average Volume (30 Days) | 5.98M |
|---|---|
| P/E Ratio (Current) | -2.88 |
| EPS (Current) | -$0.94 |
| Dividend Yield | 0.00% |
| Free Cash Flow | -$158.99M |
| Cash Ratio | 1.19 |
| Current Ratio | 8.19 |
| Quick Ratio | 8.19 |
| Debt to Equity | 0.00 |
| Enterprise Value | $571.20M |
| EV to EBITDA | -2.69 |
| EV to Sales | — |
| Price to Book | 1.93 |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | — |
| Return on Assets | -0.48% |
| Return on Equity | -0.67% |
Allogene Therapeutics Stock Splits
There have been no stock splits for Allogene Therapeutics (ALLO).
Allogene Therapeutics Dividends
There have been no dividends for Allogene Therapeutics (ALLO).